QR-Code

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Abstract Background Achieving clinical remission is a key therapeutic goal in rheumatoid arthritis (RA). While pivotal trials and early real-world studies have demonstrated the efficacy of upadacitinib (UPA), data on its impact as assessed by imaging remain limited. Here, we report the 48 weeks outc...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Andrea Picchianti Diamanti, Valentino Paci, Michele Maria Luchetti Gentiloni, Simonetta Salemi, Giorgio Sesti, Ilaria Anna Bellofatto, Caterina Baldi, Paolo Falsetti, Maria Sole Chimenti, Arianna D’Antonio, Gloria Crepaldi, Alen Zabotti, Ivan Giovannini, Marco Canzoni, Donatella Fiore, Gian Domenico Sebastiani, Chiara Scirocco, Carlo Perricone, Bruno Laganà, Annamaria Iagnocco
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2025-11-01
Schriftenreihe:Arthritis Research & Therapy
Schlagworte:
Clinical remission
Ultrasonographic remission
JAK inhibitors
Upadacitinib
Online-Zugang:https://doi.org/10.1186/s13075-025-03671-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge